KPTI
Karyopharm Therapeutics Inc
1.60$
-6.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.2% | -16.3% | -0.1% | +89.2% | -13.5% | +6.1% | -2.5% | +17.3% | -32.9% | -31.6% | -34.1% | |
| – | -14.5% | -25.9% | +12.8% | +125.4% | -18.2% | +5.8% | -4.8% | +27.1% | -33.2% | -33.1% | -34.1% | |
| – | -61.3% | -14.9% | +38.9% | +71.1% | +9.2% | -33.3% | +121.7% | -29.0% | -61.4% | +19.6% | -3.1% | |
| – | -14.6% | -26.2% | +13.1% | +124.1% | -19.6% | +3.6% | -16.4% | +21.6% | -31.1% | -43.2% | -41.4% | |
| – | – | – | – | – | – | +63.8% | +74.7% | +109.3% | -42.7% | +14.1% | -14.9% | |
| – | – | – | – | – | – | +664.2% | +55.3% | +2.9% | -28.0% | +55.7% | -14.8% | |
| – | +26.5% | -18.6% | -23.0% | +76.8% | -21.1% | -27.2% | -26.0% | -30.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.1% | +6.2% | +180.2% | +210.9% | +55.2% | +7.1% | +46.7% | -2.6% | +0.5% | -7.0% | +14.5% | |
| – | +23.0% | +8.9% | +200.2% | -5.2% | -1.2% | -99.4% | +24,720.9% | -10.6% | +5.4% | +32.8% | -0.2% | |
| – | – | – | – | +51.2% | -95.0% | +16.5% | +20.8% | +24.0% | +15.2% | +651.6% | -11.6% | |
| – | -39.4% | +24.8% | +19.2% | -23.5% | -77.3% | +351.8% | -64.0% | +73.0% | +12.6% | +63.5% | -21.6% | |
| – | – | – | – | – | +7.0% | +7.3% | +43.6% | +0.5% | +0.5% | -4.7% | +26.4% | |
| – | -4.1% | -18.2% | -20.2% | +41.5% | -72.8% | +1.6% | -257.6% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +14.4% | +5.3% | +22.3% | +1,755.6% | +9.1% | +16.3% | -93.0% | +8.8% | +39.5% | +6.7% | +34.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.